Top 10 Prefered Stocks To Invest In Right Now

MoneyShow's Jim Jubak discusses the reaction of gold prices to the government shutdown and what that may mean for the bottom in gold prices.

If you're an investor in gold or you trade gold, the government shutdown has had to be a disappointment to you. I mean, after all, if the US Government shuts down with a looming debt ceiling crisis and gold doesn't go up, what is it going to take to push gold up? One of the things that is happening here, I think, is you're seeing a reset of where the bottom might be. The consensus was that the bottom for gold was around $1200 an ounce.

Fitch came out, Fitch Ratings, one of the credit rating companies, came out and said, "Well, you know, given the fact that gold is not trading on commercial fundamentals or on actual demand, was trading as kind of a financial instrument, and given the fact that Central Bank seemed to be selling gold, or, at least, not accumulating it, maybe $1200 is not the bottom and we see a foundation at $1000."

Hot Japanese Companies To Watch For 2015: A-Cap Resources Ltd (ACB)

A-Cap Resources Limited is an Australia-based mineral exploration company. The Company�� principal activity during the fiscal year ended June 30, 2012 (fiscal 2012), is exploration of its tenement portfolio in Botswana and the ongoing feasibility studies into the Letlhakane Uranium Project. The Company focuses on investment in Botswana in Southern Africa, where it holds over 5000 square kilometer of exploration licenses. The Company�� projects include Botswana project, Letlhakane project, Mea-Coal project, Bolau-Coal project and Southern Pans project. The Company�� 100% owned Letlhakane Uranium Project is located in northeast Botswana. In July 2012, A-Cap announced the discovery of two new coal projects in Botswana, transforming the Company into a multi-commodity exploration outfit. Advisors' Opinion:

• [By John Heinzl]

  You'll notice that these numbers don't add up to $1.4988. That's because the 2012 distribution also contained a hefty chunk of return of capital (70.489 cents). ROC isn't taxable immediately; rather, it is subtracted from the adjusted cost base (ACB) of the units, which gives rise to a larger capital gain, or smaller capital loss, when the units are ultimately sold. Many REITs and mutual funds also distribute ROC. ROC can be a bit of a headache for investors. If you hold BIP in a non-registered account, you (or your accountant), will need to track those ROC payments in order to keep your ACB up to date. Knowing the ACB is necessary to calculate your capital gain, or loss, when it comes time to sell.

Top 10 Prefered Stocks To Invest In Right Now: JMP Group Inc (JMP)

JMP Group Inc., through its subsidiaries, operates as an investment banking, asset management, and corporate credit management company in the United States. The company provides various investment banking products and services, such as capital raising, mergers and acquisitions transaction, and other strategic advisory services to corporate clients. It also offers sales and trading services, which include distributing equity research products, communicating proprietary investment recommendations, executing equity trades on behalf of institutional clients, and marketing the securities of companies, as well as related brokerage services to institutional investors. In addition, the company provides proprietary equity research in five industries, including consumer, financial services, healthcare, real estate, and technology industries. Further, it provides asset management products and services to institutional investors, and high net-worth individuals; and involves in the man agement of collateralized loan obligations. JMP Group Inc. was founded in 1999 and is headquartered in San Francisco, California with additional offices in New York, New York; Boston, Massachusetts; Chicago, Illinois; and Alpharetta, Georgia.

Advisors' Opinion:

• [By Marc Bastow]

  Full-service investment banking, asset management and corporate credit management firm JMP Group (JMP) raised its quarterly dividend 13% to 4.5 cents per share, payable April 11 to shareholders of record as of March 28.
  JMP Dividend Yield: 2.41%

Top 10 Prefered Stocks To Invest In Right Now: Euro Tech Holdings Company Limited(CLWT)

Euro Tech Holdings Company Limited, through its subsidiaries and associated companies, engages in marketing and trading air, water, and waste water related process control, analytical, and testing instruments, as well as disinfection equipment and related automation systems. The company distributes a range of advanced air and water pollution control equipment, chlorination equipment, laboratory instruments, analyzers, test kits, and related supplies; and power generation related equipment, including recorders and power quality analyzers. It also manufactures air and water analytical instruments and testing equipment, as well as undertakes air, water, and waste-water treatment engineering projects. Euro Tech primarily sells its products through its retail shops and representative offices, as well as through independent sub-distributors to commercial customers, governmental agencies, or instrumentalities in Hong Kong and the People?s Republic of China. The company was found ed in 1971 and is headquartered in Hong Kong, Hong Kong.

Advisors' Opinion:

• [By James E. Brumley]

  If you're like most investors, you've probably never heard of Euro Tech Holdings Co. Ltd. (NASDAQ:CLWT). I have a confession to make - until a few days ago, I hadn't heard of it either. Yet, in just the few short days I've had to get to know CLWT, I've come to the conclusion that if you're the kind of person who would be just as comfortable taking an extra $1000 to the casino as you would be in putting that money into a brokerage account and putting into a crazy stock, then Euro Tech Holdings may be worth a shot to you.

Top 10 Prefered Stocks To Invest In Right Now: Pound/Rand(PX)

Praxair, Inc. engages in the production, distribution, and sale atmospheric and process gases, as well as surface coatings in North America, Europe, South America, and Asia. The company offers atmospheric gases, such as oxygen, nitrogen, argon, and rare gases; and process gases comprising carbon dioxide, helium, hydrogen, electronic gases, specialty gases, and acetylene. It also designs, engineers, and builds equipment that produces industrial gases; and manufactures precious metal and ceramic sputtering targets used primarily in the production of semiconductors. In addition, the company supplies surface coatings consisting of wear-resistant and high-temperature corrosion-resistant metallic and ceramic coatings and powders to the aircraft, energy, printing, textile, plastics, primary metals, petrochemical, and other industries. Further, it provides electric arc, plasma, and oxygen fuel spray equipment, as well as arc and flame wire equipment used for the application of wea r-resistant coatings; and distributes welding equipment purchased from independent manufacturers. The company sells its products primarily through independent distributors. It serves various industries, such as healthcare, petroleum refining, computer-chip manufacturing, beverage carbonation, fiber-optics, steel making, aerospace, chemicals, and water treatment industries. The company was founded in 1907 and is headquartered in Danbury, Connecticut.

Advisors' Opinion:

• [By Tom Rojas and Maria Armental var popups = dojo.query(".socialByline .popC"); ]

  Praxair Inc.'s(PX) second-quarter earnings grew nearly 5% as new projects in North America and Asia helped drive overall sales growth, but the company sounded a cautious tone for the remainder of the year. Shares were inactive premarket.

Top 10 Prefered Stocks To Invest In Right Now: SABMiller PLC (SBMRY)

SABMiller plc, incorporated on March 17, 1998, is a holding company, which has brewing and beverage interests across six continents. The Company together with its subsidiaries is engaged in the manufacture, distribution and sale of beverages. The Company is a brewer with more than 200 beer brands. The Company�� portfolio of brands includes international beers, such as Pilsner Urquell, Peroni Nastro Azzurro, Miller Genuine Draft and Grolsch, as well as local brands, such as Aguila, Castle, Miller Lite, Snow, Tyskie and Victoria Bitter. It is a bottler for the Coca-Cola Company in Africa and Central America. It operates in Latin America, Europe, North America, Africa, Asia Pacific, and South Africa.

Latin America

The Company�� primary brewing and beverage operations cover six countries across South and Central America (Colombia, Ecuador, El Salvador, Honduras, Panama and Peru). The Company is brewer in Argentina, and it exports to Bolivia, Chile and Paraguay. It bottles soft drinks for The Coca-Cola Company in El Salvador and Honduras, and for Pepsico International in Panama.

Europe

The Company�� primary brewing operations cover eight countries: the Czech Republic, Hungary, Italy, Poland, Romania, Slovakia, Spain (Canary Islands) and the Netherlands. A further 16 countries, including Russia, Turkey and the Ukraine are covered in a strategic alliance with Anadolu Efes through brewing, soft drinks or export operations. The Company exports volumes to a further seven European markets, of which the largest are the United Kingdom and Germany.

North America

The Company�� North America segment includes its 58% owned MillerCoors and 100% of Miller Brewing International and the its North American holding companies. The Company�� wholly owned Miller Brewing International business is based in Milwaukee, the United States and exports its brands to Canada and Mexico and throughout the Americas.

Africa

The Compa! ny�� brewing and beverage operations in Africa cover 15 countries. A further 21 are covered through a strategic alliance with the Castel group and it also has an associated undertaking in Zimbabwe. The Company bottles soft drinks for The Coca-Cola Company in 20 of its African markets (in alliance with Castel in 14 of these markets).

Asia Pacific

The Company�� partners with China Resources Enterprise, Limited in China. The Company is engaged in brewing business in India. The Company has operation in Vietnam and it exports to various markets, including South Korea and Singapore.

South Africa

The Company�� South African Breweries (Pty) Ltd (SAB) is South Africa�� producer and distributor of lager and soft drinks. It also exports brands for distribution across Namibia. Its soft drinks division is bottler of products for The Coca-Cola Company. The Company has hotel and gaming interests through its associate, Tsogo Sun Holdings Ltd, a hotel and gaming group in South Africa.

Advisors' Opinion:

• [By Barry James]

  LONDON -- In its final results for the year to March 31, SABMiller (LSE: SAB  ) (NASDAQOTH: SBMRY  ) , the global beverage-brewer and bottler with more than 200 beer brands and Coca-Cola bottling operations, saw group revenue increase by 10% to $34.5 billion and EBITA rise 14% to $6.4 billion, while pre-tax profit fell 16% to $4.7 billion.

• [By Tony Reading]

  I'm less familiar with South African-based SABMiller (LSE: SAB  ) (NASDAQOTH: SBMRY  ) , though its market cap is slightly larger than Diageo after its shares are up 50% over the year. I think of it as expensive, but a quick check on my data provider shows the two shares equally rated with prospective price-to-earnings (P/E) ratios of 19.7 and yields of 2.3% for Diageo and 2.2% for SABMiller. So maybe it's time to do a little portfolio rebalancing.

• [By Charles Sizemore]

  At current valuations, STZ stock is not attractive relative to its larger and better diversified megabrewer rivals — all of which have better exposure to emerging markets. As long-term holdings, I see better value in Heinken, Anheuser-Busch InBev and SAB Miller (SBMRY).

Top 10 Prefered Stocks To Invest In Right Now: Australian Dollar(AU)

AngloGold Ashanti Limited primarily engages in the exploration and production of gold. It also produces silver, uranium oxide, and sulfuric acid. The company conducts gold-mining operations in South Africa; continental Africa, including Ghana, Guinea, Mali, Namibia, and Tanzania; Australia; and the Americas, which include Argentina, Brazil, and the United States. It also has mining or exploration operations in the Democratic Republic of the Congo, Guinea, and Colombia. As of December 31, 2010, the company had proved and probable gold reserves of 71.2 million ounces. The company has a strategic alliance with Thani Dubai Mining Limited to explore, develop, and operate mines across the Middle East and parts of North Africa. AngloGold Ashanti Limited, formerly known as Vaal Reefs Exploration and Mining Company Limited, was founded in 1944 and is headquartered in Johannesburg, South Africa.

Advisors' Opinion:

• [By Holly LaFon]

  The second largest market cap company, at $11.22 billion, is Anglogold Ashanti Ltd. (AU). Its afternoon stock price of $29.15 is within 5% of its three-year low, and has experienced a more significant drop than Newmont ��it is down 44.9% from its high price of $52.86 a share.

• [By Patricio Kehoe] stion arises: Why is First Eagle bullish regarding such a company? The answer might lie in the huge discount at which the third-largest gold producer by output is trading, along with a certain degree of long-term optimism.

  Huge Holdings Point to Long-Term Commitment

  Since First Eagle recently increased its stake in Anglogold by more than 20%, bringing his total holding to over 32.5 million shares, I believe we are looking at a long-term investment. I am keen on pointing this out, since the stock is currently performing very poorly, and has already lost around 275% of its value year to date. Above average production costs and plummeting gold prices have put a huge deal of pressure on the gold miner, leading to very poor results. In addition, since many of its operations are in geopolitically risky countries such as Mali and the Democratic Republic of Congo, shareholders have been shedding this stock in large volumes.

  Although Anglogold had a very rough year, and will continue to face elevated cash costs and reduced margins going into 2014, there are some positive signals looking forward. One of the most promising features, are the firm�� operations in South America and Australia, which are enjoying solid organic growth. Although investors will have to wait some years for assets in these regions to reach full production, large profits should be achieved in the long-term. In other words, First Eagle surely has its eyes set on the company�� new projects, and their future growth potential.

  Projected Growth and Low Price

  Another attractive feature investors must keep in mind is a stock�� growth potential. When looking at Anglogold, this becomes especially relevant, as a comparison to Barrick Gold Corp (ABX) will demonstrate. Anglogold currently offers 13.6% returns on invested capital, compared to Barrick�� -2.8%, and has an EBITDA growth rate of 465.7%, the highest in the industry. Thus, whereas the Canadian miner has a negative EPS

• [By Profit Confidential]

  Graham Ehm, Executive Vice President of South African-based AngloGold Ashanti Limited (NYSE: AU), one of the biggest gold producers in the global economy, stated the company is looking to save $500 million over the next 18 months, as capital expenditures will only be going towards their highest-quality assets. (Source: Mining Weekly, August 5, 2013.)

• [By Mark Hulbert]

  If you prefer the shares of individual gold-mining companies, Freeport-McMoRan Copper & Gold (FCX) �is currently the one most recommended by the Hulbert Financial Digest-monitored advisers who have beaten the S&P 500 over the past 15 years. Also popular are Agnico Eagle Mines (AEM) , Barrick Gold (ABX) , AngloGold Ashanti (AU) �and Newmont Mining (NEM) .

Top 10 Prefered Stocks To Invest In Right Now: Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.

Duchenne Muscular Dystrophy Program

The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.

Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.

Anti-Viral Programs

The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.

The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.

The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.

AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.

Influenza Program

The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.

The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.

The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.

Advisors' Opinion:

• [By RichardCox]

  Investing in biotech can seem intimidating, given the complex nature of the industry. So, for those looking for a simple way to gain exposure to the industry, a basket sector ETF might be the best choice. The clearest option here is the SPDR S&P Biotech ETF (XBI), which has nominal gross expense ratio of 0.35% and an average return of nearly 10% since it was started in 2006. The fund's holdings include Sarepta Therapeutics (SRPT), which has made well-documented progress in Eteplirsen, its Duchenne muscular dystrophy drug. Most analysts expect Eteplirsen to receive relatively quick FDA approval, helping support the underlying value of the stock. Other holdings include NPS Pharmaceuticals (NPSP), which recently bought back the right to Gattex, a short bowel syndrome drug.

• [By Leo Sun]

  Prosensa: GSK doesn't believe in it -- so why should you?
  Throughout 2013, Prosensa and its former partner GlaxoSmithKline competed against Sarepta Therapeutics (NASDAQ: SRPT  ) to launch the first dedicated treatment for Duchenne muscular dystrophy (DMD).

• [By Brian Orelli]

  After Sarepta Therapeutics (NASDAQ: SRPT  ) announced that it was going to have a conference call today to update investors about its plans for a marketing application with the Food and Drug Administration, I joked on Twitter that the lede for my article, "I couldn't have predicted this," worked either way.

• [By Sean Williams]

  Today, we're going to take a closer look at�Sarepta Therapeutics' (NASDAQ: SRPT  ) presentation, which was delivered Wednesday by President and CEO Chris Garabedian.